The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Breast cancer incidence in patients with BRCA-related advanced ovarian cancer receiving olaparib-based maintenance therapy: A pooled analysis from phase III clinical trials.
 
Michele Bartoletti
No Relationships to Disclose
 
Marcella Montico
No Relationships to Disclose
 
Roberta Mazzeo
No Relationships to Disclose
 
Marco De Scordilli
No Relationships to Disclose
 
Lucia Musacchio
No Relationships to Disclose
 
Emilio Lucia
No Relationships to Disclose
 
Giorgio Giorda
No Relationships to Disclose
 
Samuele Massarut
No Relationships to Disclose
 
Martina Urbani
No Relationships to Disclose
 
Gianmaria Miolo
No Relationships to Disclose
 
Alessandra Viel
No Relationships to Disclose
 
Mattia Garutti
Consulting or Advisory Role - Lilly; Novartis
 
Lucia Da Ros
Consulting or Advisory Role - Lilly; Novartis
 
Simona Scalone
No Relationships to Disclose
 
Milena Nicoloso
No Relationships to Disclose
 
Serena Corsetti
No Relationships to Disclose
 
Roberto Sorio
No Relationships to Disclose
 
Domenica Lorusso
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; Merck Serono; MSD; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline; PharmaMar; Roche
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup
 
Sandro Pignata
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Fabio Puglisi
Honoraria - AstraZeneca/Merck; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Viatris
Research Funding - AstraZeneca/Merck; Eisai; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca/Merck; Celgene; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche